Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-1468 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1: mRNA-1468: Dose 1 | EXPERIMENTAL | Participants will receive placebo by intramuscular (IM) injection on Day 1 followed with mRNA-1468 by IM injection on Day 57 in Part 1. |
| Part 1: mRNA-1468: Dose 2 | EXPERIMENTAL | Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57 in Part 1. |
| Part 1: mRNA-1468: Dose 3 | EXPERIMENTAL | Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57 in Part 1. |
| Part 1: mRNA-1468: Dose 4 | EXPERIMENTAL | Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57 in Part 1. |
| Part 1: Shingrix | ACTIVE_COMPARATOR | Participants will receive Shingrix by IM injection on Day 1 and Day 57 in Part 1. |
| Part 2: mRNA-1468: Dose 5 | EXPERIMENTAL | Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57 in Part 2. |
| Part 2: mRNA-1468: Dose 6 | EXPERIMENTAL | Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57 in Part 2. |
| Part 2: Shingrix | ACTIVE_COMPARATOR | Participants will receive Shingrix by IM injection on Day 1 and Day 57 in Part 2. |
| Name | Type | Description |
|---|---|---|
| mRNA-1468 | BIOLOGICAL | Sterile liquid dispersion for injection |
| Placebo | BIOLOGICAL | Sterile liquid for injection |
| Shingrix | BIOLOGICAL | Sterile suspension for injection |
Inclusion Criteria: * Part 1: Is an adult 50 years of age or older at the time of consent. Part 2: Is an adult 50-69 years of age at the time of consent. * Has a body mass index of 18 to \<40 kilograms/meter squared at the Screening Visit. * Females of childbearing potential: have a negative pregna...
mRNA-1468 is an investigational vaccine being developed for the prevention of Herpes Zoster, commonly known as shingles. It is currently in Phase 1 clinical development and is intended for use in healthy adults aged 50 years and older.
mRNA-1468 is being developed by Moderna, Inc., a biotechnology company publicly traded under the ticker symbol MRNA on the NASDAQ stock exchange. The company is conducting clinical trials to evaluate the safety and immunogenicity of this investigational vaccine.
mRNA-1468 is currently in Phase 1 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. The ongoing Phase 1 study is evaluating its safety, reactogenicity, and immunogenicity in healthy adults aged 50 years and older.
mRNA-1468 is being studied in a Phase 1 clinical trial registered as NCT05701800. This trial is titled 'A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age' and is being conducted in the United States and Puerto Rico.
mRNA-1468 is a distinct investigational vaccine candidate developed by Moderna. It is not known to be the same as any other vaccine product. Its specific formulation and mechanism are proprietary to Moderna and are being evaluated in clinical trials for the prevention of Herpes Zoster.